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ABSTRACT

Single photon emission computed tomography (SPECT) is a medical imaging
technique which provides three-dimensional images of living systems after introduction
of a radiolabeled pharmaceutical. Rofecoxib (4-[4-methylsulphonylphenyl]-3
phenylfuran-2(SH)-one) is an inhibitor ofthe cycloxygenase-2 enzyme, an enzyme which
has been found to promote cancer cell growth. The synthesis of a no-carrier-added
iodine-123 labeled rofecoxib derivative is potentially of value for the detection of cancer
utilizing SPECT.
Iodine-123 labeled ~-(3-Iodophenyl)-4-(methanesulfonylphenyl)-SH-furan-2-one,

1, and 3-(4-Iodophenyl)-4-(methanesulfonylphenyl)-SH-furan-2-one, 2, were prepared
from the respective potassium organotrifluoroborate salts. The trifluoroborates were
prepared from a simple six step pathway.
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ChaRter 1
1.1

Introduction

NUCLEAR MEDICINE IMAGING
Utilization of boron chemistry as a means of incorporating radioactive isotopes

into pharmacologically active compounds for exploration in nuclear medicine imaging
has long been of interest in this laboratory. 1 Significant breakthroughs in radiotracer
development have resulted since the discovery of radioactivity by Henri Becquerel in
1896. 2 Radiochemical applications can be found in biology, chemistry, geology,
medicine, and pharmacology. In 1913, Hevesy pioneered the use of radio labeled
compounds in medicine and biology. 3 Since then, radiopharmaceuticals have become
very important in medicine~ A radiophannaceutical can be defined as a compound whose
medical application is dependent upon the radioactive emission of a constituent
radionuclide. 4 The chemistry ofradiolabeled agents parallels that of their nomadioactive
isomers, and therefore, their synthesis can be accomplished using similar preparative
chemistry. The use of short-lived isotopes helps to alleviate problems related to the
storage and disposal of radioactive compounds.
Nuclear medicine imaging techniques have led to the development of diagnostic
tools which provide valuable insight into physiological processes that would otherwise be
unobservable. Nuclear imaging provides a non-invasive technique in which the use of
computers, detectors, and radioactive phannaceuticals are combined to study
physiological processes in the human body. The technique requires the use of
radionuclides contained in reagents that are administered to the patient. 5 The
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radionuclide decay is then observed by a series of radiographic and computed
tomographic techniques.
Positron emission tomography (PET) and single photon emission computer
tomography (SPECT) are two tomography techniques that are now accepted as diagnostic
tools for a variety of tumors, illnesses, blood flow problems, aneurysms, and organ
dysfunctions. 6 A detailed discussion of nuclear imaging theory is beyond the scope of
this thesis. However, some insight into the principles of both PET and SPECT is
necessary to understand the choice of the target molecules that will be further discussed
in this thesis.
PET is a nuclear medicine procedure in which the presence ofpositron emitters
such as IIC, 13N, 150, and 18F are detected by a tomographic imaging system. A low dose
of a radiopharmaceutical labeled with one of these positron emitters is injected into the
patient and the resultant radioactive decay is observed in an emission scan, either
dynamic or static. SPECT is a nuclear imaging technique that uses nuclei that decay via
a single photon disintegration. These include iodine-l 23, technetium-99m, thallium-20l,
gallium-67, and indium-Ill. Iodine-123 is readily available.
Positrons are fonned when neutron-deficient nuclei of low atomic number decay
to more stable nuclei. 7 This decay occurs via two possible pathways: positron emission
or electron capture. PET utilizes positron emission via positron annihilation, while
SPECT utilizes photons via electron capture. Positrons have a finite lifetime with a short
mean free path, typically a few millimeters. The positron annihilates by colliding with an
electron.

This annihilation reaction between a positron and an electron produces two

0.511 MeV gamma rays, that travel in opposite directions, and are detected by two
2

detectors in parallel planes. PET utilizes opposed detectors to count the photons which
must reach the detectors within a certain time frame of the annihilation. SPECT uses
only one detector, thus eliminating the time relationship. The raw data sinograms are
reconstructed into a cross-sectional image which provides regional concentration
measurements of the radiopharmaceutical.
Many factors affect emission computed tomography (ECT). Radionuclide decay,
biokinetics of the pharmaceuticals, imaging systems, organ motion and location are just a
few of these factors which consequently affect the detennination ofnuclide
concentrations. 8 Physical and mathematical factors arising from the algorithms used to
reconstruct data also affect ECT. 9 Future developments to alleviate some of these
challenges include better detectors, more efficient algorithms, and other compensatory
techniques such as reduction of scatter.
Researchers are aggressively exploring the developments ofradiopharmaceuticals
for ECT. Initial experiments in nuclear imaging focused on the uptake ofradionuclides
in the brain that exhibited little retention. Radiolabeled agents that crossed the blood
brain barrier were a subsequent focus of development. 4 Once that goal was reached,
evolution ofradiopharmaceutical development occurred rapidly. Classes of compounds
that have emerged from development in ECT since the pioneering studies involving
placement of radionuclides in the brain continue to increase on a daily basis and include a
broad spectrum of body organs to which they can be applied. The specific action of the
carrier molecule is thought to be the same as the corresponding non-labeled molecule,
thus creating a versatile avenue for the introduction of radionuclides into a wide variety

3

of compounds. 10 One class of compounds, the cyclooxygenase (COX) inhibitors, has
gained intense interest.

1.2

COX INHIBITORS

1.2.1

Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Inflammation can be defined as the first response ofthe immune system to

infection or irritation. 11 Clinically the features of inflammation are heat, redness,
swelling, and pain. The host attempts to limit the extent of damage, counteract infection,
and promote healing as well as recovery of function. 12 The inflammation process
involves blood cells from bone marrow, and many organs are effected by inflammation to
varying degrees. These can include the central nervous system, cardiovascular system,
liver, and the endocrine system. Inflammation can be acute or chronic, and it contributes
to all disease processes.
Anti-inflammatory agents' origins can be traced back to ancient times when
people chewed on willow tree bark for pain relief. Hippocrates described the use of
salicin for pain relief in the 5th century B.C.E. Aspirin, a derivative of salicylic acid, was
discovered in 1899,13 Aspirin has been noted to have elevated risks when taken long
term such as the development of gastrointestinal bleeding, ulcers, and kidney damage.
Other anti-inflammatory drugs like ibuprofen and naproxen produce some of the same
destructive effects.

1.2.2 COX Enzymes
To understand why anti-inflammatory drugs caused the effects observed, research
was conducted to determine exactly how aspirin and other NSAIDs functioned. A British

4

phannacologist by the name of John R. Vane proposed that prostaglandins are produced
within the body's cells by the enzyme cyclooxygenase (COX).I4 NSAIDs work to inhibit
the production ofprostaglandins by blocking the COX enzyme. With the COX enzyme
inhibited, inflammation, pain, and fever subside. Two COX enzymes exist, COX-l and

COX_2.IS Both enzymes produce prostaglandins that promote pain, inflammation, and
fever. They differ in that COX-l produces prostaglandins that protect the stomach and
support platelets; inhibition of COX-I enzymes by NSAIDs reduces platelets, thereby
causing ulcerative bleeding.
COX-2 inhibitors gained interest with the finding that COX-2 is associated with
inflammatory conditions and COX-l is expressed as a constitutive enzyme. IS COX-l
synthesizes prostaglandins for physiological functions such as renal blood flow regulation
and cell division. COX-2 is induced by two types of cellular messengers: inflammatory
cytokines and growth factors. Both of these processes promote the initiation of cancer
cell growth and survival. I6,I7 The inhibition of COX-2 is believed to induce the anti
inflammatory effects, while COX-1, inhibition causes the destructive effects to the
stomach and liver. IS
The above factors led phannaceutical companies to invest vast resources into
developing classes of compounds that targeted COX-2 while allowing expression of
COX-I. In 1999, SearlelMonsanto brought celecoxib onto the market for the treatment
of arthritis. Soon after the introduction ofcelecoxib (celebrex®), Merck introduced
rofecoxib (vioxx®), which has recently been the subject of many investigations. Pfizer
marketed valdecoxib (bextra®). Many other phannaceutical companies followed with
the introduction of various COX-2 inhibitors. Among these are Glaxo Smith Kline,
5

Novartis, Roche, Parke Davis, Boeringer-Ingelheim, Abbott Laboratories, Procter and
Gamble, DuPont and others. There are many classes of compounds that make up the
COX-2 inhibitor familyI5.19: thiazoles,oxazoles, 1,5-diarylpyrazoles, ethers, thioethers,
cyclopentenes, cyclobutenones, cyclopentones, fused heterocycles, pyridazinones, 2,3
diarylbenzopyrans, 1, 1-dihalo-2,3-diphenylcyclopropanones, pyrimidin-2-amines, and
3,4-diarylfuranones. The advantage of these drugs is that they reduce inflammation
without the harsh side effects of earlier NSAIDs such as ulcerative bleeding and liver
damage.
Since both COX-1 and COX-2 catalyze the conversion of arachidonic acid to
prostaglandin, understanding what differentiates these enzymes on the molecular level
aided in the development ofthe selective inhibitors. The COX enzymes have a specific
orientation within the cell membrane. Four amphipathic helices form a hydrophobic
surface that floats these enzymes in the upright position on the membrane. 2o The helices
make up the base of the molecule, and form the opening to a hydrophobic pocket on the
inner membrane surface of the enzyme, which is the COX active site. 2o As these helices
are embedded within the membrane, fatty acids and NSAIDs must cross the lipid bilayer
to reach the COX active site entrance.
Arginine, in the charged form, is present in the COX-1 active site position 120. 21
COX-1 activity is dependent on the lock and key fitting of fatty acid substrates with
Arg 120 within the site. Replacing arginine with lysine changes the activity ofCOX_1.21
This illustrates that a single amino acid can affect the activity of a particular enzyme,
thereby opening a gateway for designing selective COX inhibitors.

6

1.2.3 COX-2 Inhibitors and Carcinogenesis
Kune discovered that individuals who consumed aspirin on a daily basis had a
40% lower risk of colon cancer than those who used no aspirin.

22

Later, the expression of

the COX-2 enzyme was noted in 85% human colorectal carcinomas. 23 Following this
observation, sulindac (a NSAID) was found to eliminate rectal polyps, thus giving insight
to the possibility that NSAIDs might be a possible treatment for tumors. 24

In vitro studies with cell lines derived from adenocarcinomas of the lungs,
pancreas, colon, stomach, breast and prostate, as well as relevant animal studies and
epidemiological studies in humans, have provided evidence that cyclooxygenase
inhibitors (both COX-l and COX-2) can significantly reduce the risk for development of
this cancer family.25-36 Cyclooxygenase inhibitors are thus being evaluated in cancer
prevention and treatment trials. 36-39 Recent reports have revealed that the chronic use of
COX-2 inhibitors may increase the rate of cardiovascular morbidity.4o Monitoring
patients undergoing chronic treatment with COX-2 inhibitors prior to and during therapy
could become important in the future. Nuclear medicine imaging utilizing SPECT or
PET might help in this regard. We have developed a rapid and convenient method for
preparing two iodine-123 labeled rofecoxib analogues (Figure 1, page 8). The synthetic
methods utilized in the preparation of these radiopharmaceuticals are outlined in this
thesis.

7

Rofecoxib

Figure 1. Rofecoxib and Iodine-123 labeled rofecoxib analogues
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ChaI!ter 2
2.1

Approach to the Study

RATIONALE FOR SYNTHESIS OF ROFECOXIB DERIVATIVES
The iodine-l 23-labeled 3-iodo analogue ofrofecoxib 1 was chosen for the study

because the related 3-chloro derivative was well-tolerated in a rat paw edema assay, with
EDso values comparable to rofecoxib.

41

The iodine-123-labeled 4-iodo analogue ofrofecoxib 2 was chosen for the study
based on the fact that substitution of a halogen (including bromine and chlorine as well as
other large electron withdrawing groups) at the para position does not significantly alter
COX-2/COX-l selectivity.41-4S In a rat paw edema assay, para-substituted bromo and
chloro derivatives displayed EDso values comparable to rofecoxib itself. 42,43 A para
substituted sulfonamide derivative proved to be even more effective than rofecoxib. 4s

2.2

PREVIOUS SYNTHETIC ATTEMPTS AT ROFECOXIB DERIVATIVES
Two paths were explored prior to arriving at the current method for preparing the

prerequisite iodinated precursors to the targeted meta and para iodine-123 rofecoxib
analogues. They differ in the sequence in which the trifluorborate rofecoxib precursor is
assembled. One path followed the synthetic pathway developed by Desmond, Dolling,
Marcune, Tillyer, and Taschaen,42 and is outlined in Scheme 1, page 10. This route was
abandoned early on in the study as many difficulties were encountered in achieving
acceptable yields of the necessary furanone. Many reaction conditions were explored in
which the stoichiometric amounts of base used and the reaction time were varied.
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Toluene, ElOH
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However, none ofthese methods resulted in improved yields. Furthermore, no
correlation could be made as to what conditions were ideal.

A second potential route involved building the molecule as shown in Scheme 2,
page 12. This pathway involved conversion of meta-iodophenylacetic acid to a methyl
ester, from which the boronic ester moiety was formed. However, upon cleavage of the
methyl ester, the boronic ester was also converted to the boronic acid giving undesired
results. This pathway was also abandoned.
A more simplistic, shorter pathway was sought and found in the literature. 46 This
pathway, with few deviations was followed to arrive at the trifluoroborate rofecoxib
precursors which were suitable for radioiodination. The synthetic pathway is discussed
in the following section.

2.3

BACKGROUND
The successful route to the meta iodine-123 radio labeled rofecoxib analogue is

shown in Scheme 3 on page 13.47 The para iodine-123 radiolabeled rofecoxib analogue
is readily prepared in the same manner, using 4-iodophenylacetic acid in the coupling
reaction along with 6. This is shown in Scheme 4 on page 14. The following discussion
provides the background to each synthetic step.

2.3.1

Friedel Crafts Acylation

The first step in the synthesis of the trifluoroborate rofecoxib precursor 9 utilizes a
Friedel-Crafts acylation. This involves the formation of an aryl ketone via electrophilic
substitution utilizing an aryl compound, an acid halide, and a Lewis acid as a catalyst.
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Since the reagent used here is thioanisole, the sulfur acts as an activating group,
enhancing the electrophilic substitution reaction. The sulfur group is an ortho-para
directing group, therefore the para product is formed in relatively high yields. 48
The desired reaction is achieved by cooling the Lewis acid in chloroform to 0 °c,
slowly adding the acid chloride and the aryl reagent, and allowing the reaction to proceed
while warming to room temperature. The reaction is quenched by cooling it to 0 °c,
adding water while stirring, and subsequent washing with water, sodium bicarbonate, and
brine to remove residual starting materials. Common reagents for Friedel-Crafts
acylations are used: thioanisole as the aryl component, acetyl chloride, and aluminum
chloride as the Lewis acid catalyst.
The mechanism involves the formation of an acylium ion (Step 1, Scheme 5, page
16) rather than a carbocation, which is common in carbon-carbon bond formations. The
acylium ion then adds to the aromatic ring to produce an intermediate arenium cation,
which is resonance stabilized (Step 2, Scheme 5). Removal of the proton from the
arenium cation is the fmal step in the reaction, which is achieved by the base (Step 3,

Scheme 5).
2.3.2

Oxidation of the Sulfur Substituent
The second step in the reaction sequence involves oxidation of the sulfur atom to

the requisite sulfone. In order to achieve the desired degree of oxidation, an
organometallic peroxide is used which coordinates to the sulfur, and efficiently oxidizes
it. One can envision that this occurs via a coordination mechanism.

15

Step 1

Step 2

•

[j0

Step 3
R

0

O
I~
~

Scheme 5. Friedel Crafts acylation mechanism

16

+ HCI

+ AICl3

2.3.3 Bromination Reactions of Ketones
The third step in the sequence occurs via a-bromination of the ketone.
Halogenations at the alpha position of aldehydes and ketones are possible with bromine,
iodine, and chlorine. 49 Generally, the order of halogenation in an asymmetric ketone is
CH > CH2 > CH3. Halogenations can be difficult to control, as they proceed until all of
the halogen is used in base. Therefore, careful consideration much be taken in
calculating the stoichiometric amounts of both the ketone and halogen. AI: 1 molar ratio
must be used, or by-products such as the dihalogenated analogues contaminate the
product. In a bromination involving a methyl ketone, the reaction can proceed via a
haloform reaction. Haloform reactions usually produce a carboxylic acid. However, in
this particular reaction sequence, low temperatures efficiently provide a method to halt
the reaction at the desired point. An acid catalyst, AICI3, and cold temperatures initiate
the formation of the enol. The reaction is allowed to wann to room temperature and
proceeds via the mechanism shown in Scheme 6, page 18.
The reaction progress is monitored by thin layer chromatography (TLC), and
upon disappearance of the starting material, the reaction is cooled to 0 °C. Water is
added to quench the reaction. Subsequent washings with brine ensure completion of the
workup.

2.3.4 Furanone Ring Formations
The most difficult step in the synthesis involves the furanone ring formation.
Typically, these rings are cyclized from a diketo ester moiety in the presence of a strong
base. 50 Yields are generally on the order of.. . .50%. The reaction involving the furanone
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ring formation is accomplished via an in situ coupling of the a.-bromo ketone precursor
and iodophenylacetic acid, followed by cyclization. The reaction can be accomplished in
a one pot, two step synthesis, using a strong base, triethylamine (to initialize the
coupling) and an additional base, 1,8-diazabicyclo[5,4,0]-undec-7-ene (DBU), to afford
the furanone moiety.47 However, with hindered starting materials, such as 3
iodophenylacetic acid, ring closure is somewhat inhibited.
This barrier can be overcome with the use of microwave chemistry. Microwave
chemistry can be utilized in a variety of organic transformations. It provides a facile
means of transforming organic compounds in short reaction times. Many variables can
be controlled in microwave synthesis such as temperature, reaction times, and power.
Reactions can even be accomplished in solvent-free environments. Microwave chemistry
systems are so advanced that they can be programmed to control power, ramp, time, and
other variables such that complex syntheses can be readily achieved.
The reaction to form the desired furanones proceeds in good (50%) yields. The
two starting materials are dissolved in a solvent and an excess of base is added. The
reaction vial is microwaved for a short period of time and then allowed to cool to room
temperature. Acidification initiates precipitation of the product, which is then purified
with column chromatography.

2.3.5 Suzuki Coupling
Boronic esters have become quite useful in organic synthesis. 51 They are readily
coupled to aryl electrophiles via organometallic chemistry employing palladium
catalyzed cross-coup lings. 52 A simple one pot synthesis is available for converting aryl
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halides to arylboronic esters via a palladium cross-coupling reaction utilizing
bis(pinacolato)diboron, an aryl halide, and a base as shown in Scheme 7, page 21. 52
Refluxing temperatures are required for the reaction to proceed. A weak: base
such as potassium acetate provides the best yields while bases such as potassium
phosphate and potassium carbonate give byproducts such as biphenyl. Polar solvents
work best and increasing the solvent polarity accelerates the reactions. The reaction rates
in various solvents decrease in the following order: DMSO > DMF > dioxane> toluene.
Benzene may also be used as a solvent.
1,1-Bis(diphenylphosphino)ferrocene dichloro palladium is the most efficient
catalyst for arenes possessing electron-withdrawing or electron-donating substituents.
Electron-withdrawing substituents accelerate the rate of reaction, while substituents with
electron-donating substituents require longer reaction times. Reaction times may be as
short as one hour or as long as 24 hours. Grignard or lithium reagents require functional
group protection, but many functional groups are tolerated in the coupling reaction itself,
e.g., nitriles, ethers, and esters. Sterlc hindrance does not pose a barrier to successful
coupling. Heteroaromatics reagents also readily react.
Suzuki coupling is believed to occur via the oxidative-reductive palladium cycle
shown in Scheme 8, page 22. The haloarene undergoes oxidative addition to the
palladium(O) complex giving a ArPd(II)X adduct. Transmetallation occurs between the
diboron substrate and the palladium adduct to give a ArPd(II)B(OR)2 intermediate.
Reductive elimination produces the recycled palladium(O) complex and the desired aryl
boronic ester. While the mechanism of the transmetallation is not completely understood,
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it is believed that the base generates the acetoxopalladium(II) species by displacing the
palladium halide; it is this species that coordinates with the diboron substrate.

2.3.6

Conversion of Arylboronic Esters to Potassium TriOuoroborates
Potassium aryltrifluoroborates are now widely used as intennediates in organic

synthesis. 53 They are chemically reactive salts that are both air and water stable. 54
Potassium trifluoroborates are readily prepared from the corresponding boronic ester and

KHF2 in methanol. The preparative reaction tolerates a variety of functional groups.
The reactions of trifluoroborates proceed via ligand exchange in weakly acidic
media. It has been suggested by Thierig and Umland that the fluoroborate anion is
thennodynamically more stable than the neutral boron species, and therefore, the product
culminates from "ate" dissociation and hydrolytic cleavage. 55
The preparation oftrifluoroborates is straightforward. A solution ofthe boronic
ester is dissolved in methanol along with saturated aqueous KHF2. Precipitation of the
potassium trifluoroborate product immediately occurs. The solvent is removed, and the
salt is recrystallized from acetonitrile and acetone, producing a powdery solid.

2.3.7 Radioiodinations of Trifluoroborate Salts
Our laboratory has been interested in radiohalogenated pharmaceuticals for over
20 years56-59 Previously, boronic acids, organoboronates and organometallics were
utilized to synthesize radio labeled compounds. The boronic acids were used under
highly basic conditions, which proved detrimental to substitutents like esters and
ketones.} Many organometallic reagents are undesirable since they can be difficult to
separate from the desired radiohalogenated product. Furthennore, organometallics, such
as organotin reagents, involve the use ofheavy metals that have toxic effects on
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humans. 60 Boronic esters have been successfully utilized, but their preparation is often
difficult. Trifluoroborate salts are readily separated from reaction mixtures due to their
ionic nature. This, combined with their stability, makes them attractive for use in
radiohalogenation reactions.
We developed a radiohalogenation method utilizing boron reagents in 1984. S9
Since that time, the method has been improved and now can be applied to a wide variety
of organic compounds. Reactions of substrates with electron-donating substituents are
rapid and produce yields above 70%, while reactions of substrates with electron
withdrawing substituents require longer reaction times and produce more modest yields. S6
A wide variety of functional groups are tolerated, however, the presence of a nitro group
has been found to be detrimental. Heterocycles are also tolerated, as are
vinyltrifluoroborates. S6
The reaction itself is straightforward. Radiohalogenations are carried out in
aqueous tetrahydrofuran (THF) using no-carrier-added sodium [I23I]iodide and an
oxidant. A solution of trifluoroborate in aqueous THF is added to the no-carrier-added
Na I23I in aqueous sodium hydroxide. A solution of peracetic acid is added, and the
reaction is allowed to stir in the dark until completion of the reaction, normally less than
15 minutes. Sodium thiosulfate is added to decompose the excess iodine, and the product
is isolated using Sep-Pak filtration.
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Chanter 3

Results and Discussion

The synthesis of a no-carrier-added iodine-123 labeled analogue of rofecoxib, 1,
is outlined in Scheme 3. Thioanisole, 2, was converted to the requisite potassium
trifluoroborate salt 8 in six steps. This synthetic pathway provided the meta and para
analogues ofrofecoxib. A total of six previously unknown compounds were synthesized:
3-(3-iodophenyl)-4-(methanesulfonylphenyl)-5H-furan-2-one, 4-(4-methanesulfonyl
phenyl)-3-[3-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenyl]-5H-furan-2-one,
potassium 3-(3-trifluoroboro)-4-(4-methanesulfonylphenyl)phenyl-5H-furan-2-one, 3-(4
iodophenyl)-4-(methanesulfonylphenyl)-5H-furan-2-one, 4-(4-methanesulfonylphenyl)
3-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2yl)phenyl]-5H-furan-2-one, and
potassium 3-(4-trifluoroboro)-4-(4-methanesulfonylphenyl)phenyl-5H-furan-2-one. Both
3-(3-iodophenyl)-4-(methanesulfonylphenyl)-5H-furan-2-one and 3-(4-iodophenyl)-4
(methanesulfonylphenyl)-5H-furan-2-one are iodinated analogues ofrofecoxib which,
when labeled form with iodine-123, could be used as an imaging agent in nuclear
medicine.
The first half of the synthesis was straightforward, with only recrystallization
required to arrive at pure products. Washing the reaction mixtures with water, saturated
sodium bicarbonate, and brine provided the desired products. Ketone 4 was prepared
according to the literature procedure46 by Friedel-Crafts acylation ofthioanisole 3.
Distinct color changes signaled the reaction's progress. The cold reaction mixture
developed a deep blue color upon the addition of all the reagents. The reaction was
cooled to 0 °C and quenched by the addition of water. This produced a yellow color in
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the organic phase. Further sequential washings with water, aqueous sodium bicarbonate,
and brine lightened the yellow color, indicating removal ofresidual starting material.
Yields greater than 80% were achieved after recrystallization. Proton eH) and carbon
(13C) NMR spectra were obtained and are presented in Appendix 1. The IH NMR
assignments are shown in Figure 2 on page 27; the BC NMR assignments are shown in

Figure 3 on page 28.
Oxidation of 4 using MMPP (magnesium (bis)monoperoxyphthalate hexahydrate)
afforded sulfone 5 in 95% yield. This reaction provided a very clean product that needed
no recrystallization,. Its IH and BC NMR spectra are presented in Appendix 1. The IH
NMR assignments are shown in Figure 2 on page 27; the 13C NMR assignments are
shown in Figure 3 on page 28.
Sulfone 5 was allowed to react with bromine in chlorofonn at OoC in the presence
of a trace amount of A1Cb. A distinct color change, from dark red to light orange,
signaled the end of the reaction. The reaction was quenched with water and a color
change occurred (light orange to clear and colorless) to generate 6 in 85% yields. It was
noted that allowing this reaction to run longer than 1 hour led to increased contamination
of the product with the dibromoketone. The IH and l3C NMR spectra of the product
obtained are presented in Appendix 1. The 1H NMR assignments are shown in Figure 2
on page 27; the l3C NMR assignments are shown in Figure 3 on page 28.
During the second stage of the synthesis, column purification was a necessity at
every step. However, the columns were run in a short time frame, to achieve rapid
separation. Bromoketone 6 was coupled with 3-iodophenylacetic acid and then cyclized

in situ in the presence of 3 molar equivalents of triethylamine using microwave
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irradiation to afford 7 (the non radioactive analogue of the target molecule 1). The
product was precipitated out of the reaction mixture by acidification. Completion of the
reaction was evidenced by a color change from a dark brown mixture to a bright yellow
precipitate. Column purification provided pure crystalline product in 50% yield. The
presence of the dibromoketone impurity in the bromoketone did not markedly affect the
coupling reaction, and it was removed during column purification.
A sample of the product was submitted for high resolution mass spectroscopy
(HRMS); the results of which are presented in Appendix 2.

The sample gave a

molecular ion peak: at 439.9572 mass units, 0.0002% difference from the calculated value
of 439.9579 for the meta-iodo rofecoxib analogue. The IH and 13C NMR spectra are
presented in Appendix 1. The IH NMR assignments are shown in Figure 2 on page 27;
the 13C NMR assignments are shown in Figure 3 on page 28.
Compound 7 was converted to boronic ester 8 using Suzuki-Miyaura chemistry.25
Thin layer chromatographic analysis revealed 3 spots, indicating that byproducts were
formed during the coupling. Careful purification via column chromatography produced 8
in 57% yield. The reaction time was longer than expected, and it is suspected that the
hindered position of the coupling site was a contributing factor.
A sample of the boronic ester 8 was submitted for elemental analysis. The carbon
analysis showed 63.17%, a difference of 0.43% from the calculated value of 62.74%.
Hydrogen analysis revealed 5.92%, a difference of 0.2% from the calculated value of
5.72%. Sulfur analysis indicated the compound contained 7.03% sulfur, a difference of
0.25% from the calculated value of 7.28%. This confirmed that 8 had been successfully
prepared and characterized. The IH and l3C NMR spectra are shown in Appendix 1. The
29

IH NMR assignments are presented in Figure 2 on page 27; the 13e NMR assignments

are shown in Figure 3 on page 28.
Addition ofKHF2 to 8 then generated 9.55 Recrystallization afforded a 65% yield
of the desired product. A sample of 9 was submitted for elemental analysis and high
resolution mass spectrometry after drying at elevated temperatures in vacuo. The
elemental analysis revealed that the compound contained water ofhydration. The HRMS
(shown in Appendix 2) revealed a peak at 381.2 mass units, a difference of 0.03% from
the calculated value of 381.1 for the peak of the trifluoroborate salt. This confirmed that
the compound was formed. The IH, Be, and 19p NMR spectra are presented in Appendix
1. The IH NMR assignments are shown in Figure 2 on page 27; the Be NMR
assignments are shown in Figure 3 on page 28.
The trifluoroborate salt of the para rofecoxib analogue was also synthesized in a
parallel manner. 4-Iodophenylacetic acid was coupled to bromoketone 6 and then
cyclized in situ using microwave irradiation to afford 10, the para-iodo rofecoxib
analogue (the non radioactive analogue of the target molecule 1) in 52% yield. Its HRMS
is presented in Appendix 2, with a mass ion peak at 439.9584 mass units, a 0.05%
difference from the calculated value of 439.9579. The IH and Be NMR spectra are
shown in Appendix 1. The IH NMR assignments are presented in Figure 2 on page 27;
the Be NMR assignments are shown in Figure 3 on page 28.
The para-iodo rofecoxib analogue was converted to the para boronic ester
analogue, 11 using Suzuki-Miyaura chemistry. 52 This reaction proceeded more rapidly
and efficiently than that of the meta analogue in 67% yields. A sample of the pure
compound was submitted for HRMS, with a mass ion peak at 440.1461, a difference of
30

0.0002% from the calculated value of 440.1469. The IH and BC NMR spectra are shown
in Appendix 1. The IH NMR assignments are shown in Figure 2 on page 27; the

13C

NMR assignments are shown in Figure 3 on page 28.
The trifluoroborate salt, 12 was prepared by the addition of KHF2 in 70% yield. 55
The compound was submitted for elemental analysis. The elemental analysis revealed
that the compound contained water ofhydration. The carbon analysis showed 46.36%, a
difference of 0.23% from the calculated value of 46.59%. Hydrogen analysis revealed
3.39%, a difference of 0.06% from the calculated value of3.45%. Sulfur analysis
indicated the compound contained 7.22% sulfur, a difference of 0.1 0% from the
calculated value of 7.32%. This confirmed the identity of the new compound. The 1H,
BC, and 19F NMR spectra are presented in Appendix 1. The IH NMR assignments are
shown in Figure 2 on page 27; the 13C NMR assignments are shown in Figure 3 on page
28..
We then utilized our recently developed radio iodination procedure to generate the
no-carrier-added radioiodination products. 56 The radiochemical purity of 1 (Rr = 0.36)
determined by radio-TLC, shown in Figure 4, page 32, was 92% with a decay corrected
yield of 37%. The radiochemical purity of2 (Rr = 0.36) determined by radio-TLC,
shown in Figure 5, page 33, was 98% with a decay corrected yield of 42%. Decay
corrected yield is a radiochemical yield, in which the yield is corrected for the time
dependent decay of the radionuc1ide. As was expected, the meta analogue showed lower
yields throughout the synthesis than the para derivative.
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The procedure is unique in that the reactive intennediates (8 and 12 in this study)
are ionic in contrast to the lipophilic radio labeled products. This facilitates product
purification. Indeed, separation of the ionic trifluoroborate precursors from 1 and 2 is
readily achieved using simple Sep-Pak filtration which greatly facilitates product
recovery.
HPLC separation of the radio labeled product was deemed unnecessary since TLC
analysis of the eluent obtained after Sep-Pak separation showed no evidence of starting
material or hydrolyzed byproducts using ultraviolet light, phosphomolybdic acid, or
iodine visualization. In addition, unlike the situation in which the goal is to detect limited
numbers ofneuroreceptors, cyc100xygenase enzymes are over expressed obviating the
need for extraordininarily high specific activity levels. It is noteworthy that the
radiochemical purity of the products exceeds 92% as revealed by radio TLC.
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Cha)!ter 4
4.1

Ex)!erimentai Section

GENERAL METHODS
Proton (lH) and carbon (13C) nuclear magnetic resonance (NMR) spectra were

acquired either on a Bruker AC250 at 250.13 and 62.89 MHz, or on a Varian Mercury
300 at 300.09 and 75.46 MHz respectively. Chemical shifts are reported in parts per
million (ppm) referenced to trimethylsilane (TMS) using residual protons in deuterated
solvents for measurement. The splitting patterns are abbreviated as follows: s = singlet,
bs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt =
doublet of triplets, and m =.multiplet. Fluorine e9p) NMR spectra were obtained on a
Varian Mercury 300 at 282.33 MHz. The mass spectral analyses were obtained on a VG
Quattro II electrospray mass spectrometer. Elemental analyses were performed by
Atlantic Microlab, Inc., Norcross, GA. Melting points were determined on a Barnstead
Thermolyne melting point apparatus and are uncorrected.
All commercial reagents were purchased from Aldrich Chemical Co., Milwaukee,
WI, and used as received without further purification unless otherwise noted. All

solvents were reagent grade and were distilled from appropriate drying agents under a
nitrogen atmosphere prior to use. A CEM Discover microwave was utilized in the
coupling and cyclization synthesis.
Column chromatography was performed using silica' gel (60 A, 32-63 mesh)
obtained from Bodman Chemical, Aston, PA. Analytical thin layer chromatography
(TLC) was performed using 250 Ilm silica gel plates obtained from Analtech, Newark,
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DE, which were visualized with ultraviolet illumination at 254 run, phosphomolybdic
acid, or development in an iodine chamber. The pH of solutions was determined using
Whatman pH Indicator Paper.
Radio-TLC was carried out using a Bioscan Autochanger AR-2000 imaging
scanner. Na I23 J (specific activity = 1.93 x 106 Ci/g) was obtained from Nordion Inc.,
Vancouver, Canada.
All glassware, syringes, and needles were dried in an oven and cooled under
nitrogen prior to use.

4.2

EXPERIMENTAL PROCEDURES FOR SYNTHESIS OF POTASSIUM 3

(3-TRIFLUOROBORO)-4-(4-METHANESULFONYLPHENYL)PHENYL-5H
FURAN-2-0NE, 9

4.2.1

Synthesis of 1-(4-MethyJsuHanyJphenyJ)ethanone, 4.47
To a cold (0 °C) solution of AICb (6.8 g, 51 mmol) in CHCb (50 mL) was added

acetyl chloride (4.0 mL, 55 mmol) while maintaining the temperature below 10°C.
Thioanisole 3 (5.2 g, 5.0 mL, 42 mmol) was then added while maintaining the
temperature below 5°C; additional CHCb (20 mL) was added to facilitate stirring. The
mixture was allowed to warm to room temperature while stirring. After 2 hours, the
mixture was cooled to 10°C. Water (20 mL) was slowly added and the layers separated.
The organic layer was washed sequentially with water (2 x 30 mL), saturated aqueous
NaHC03 (2 x 50 mL) and brine, and then dried over anhydrous Na2S04. The solvent was
removed under reduced pressure and the residue was recrystallized from a hexane/ethyl
acetate solution to afford an off-white solid, 6.32 g (89.3%); m.p. 81-82 °C; IH NMR
36
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(300 MHz, CDCh): 02.49 (s, 3H), 2.54 (s, 3H), 7.23 (d, 2H, J = 8.7 Hz), 7.83 (d, 2H, J =
8.7 Hz); 13C NMR (300 MHz, CDCh): 0 15.0,26.6, 125.2, 128.9, 133.7, 146.1, 197.4.
4.2.2

Synthesis of 1...(4...Methanesulfonylphenyl)ethanone, 5.47

To a solution of 4 (1.7 g, 10 mmol) in a mixture ofMeOH (10 mL) and CH2Ch
(30 mL) was added magnesium bis(monoperoxyphthalate) hexahydrate {MMPP) (7.5 g,
15 mmol) over a 30 min period. The mixture was stirred at room temperature for 2.5 h,
filtered, and the filtrate washed with saturated aqueous NaHC03 and then brine. The
organic layer was removed under reduced pressure to give 1.89 g (95%) of 5 as a white
solid; m.p. 129-130°C; IH NMR (250 MHz, CDCh): 02.67 (s, 3H), 3.09 (s, 3H), 8.06 (d,
2H, J = 8.6 Hz), 8.14 (d, 2H, J = 8.6 Hz); 13C NMR (250MHz, CDCh): 026.9,44.3,
127.6, 129.1, 141.0, 144.2, 196.6.
4.2.3

Synthesis of2-Bromo-l-(4-methanesulfonylphenyl)ethanone, 6. 47

Ketone 5 (2.0 g, 10 mmol) was dissolved in CHCh (20 mL) and cooled to O°C.
AICh (2.0 g, 10 mg) was added, followed by a solution of bromine (0.5 mL, 10 mmol) in
CHCh (10 mL). The ice bath was removed and the solution stirred at room temperature
until completion of the reaction (TLC). Water (50 mL) was added to the reaction mixture,
and the organic layer was separated. After washing the organic layer with brine and
drying over Na2S04, the solvent was removed under reduced pressure. The residue was
recrystallized from ethyl acetate-hexane (1:1) to give pure product (2.4 g, 85%); m.p.
127-129°C; IH NMR (250 MHz, CDCh): 03.10 (s, 3H), 4.47 (s, 2H), 8.08 (d, 2H, J =
8.5 Hz), 8.17 (d, 2H, J = 8.5 Hz); l3C NMR (CDCI3): 030.1,44.2, 127.9, 129.8, 137.9,
144.9, 190.2.
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4.2.4

Synthesis of 3-(3-Iodophenyl)-4-(methanesulfonylphenyl)-SH-furan-2-one, 7.
Ketone 6 (0.29 g, 1.05 mmol) and 3-iodophenyl acetic acid (0.22 g, 1.0 mmol)

were dissolved in acetonitrile (10 mL) in a clean, dry microwave tube. Triethylamine
(0.42 mL, 3.0 mmol) was slowly added with stirring. The tube was then placed in the
microwave and irradiated at 150 Watts for 20 minutes. The mixture was acidified with
aqueous INHCI (color changed from dark brown to light yellow). A mixture of ice and
water (50 mL) was added with stirring. The precipitate was filtered, rinsed with water,
dissolved in CH2 Ch (20 mL) and then dried over anhydrous MgS04. The filtrate was
concentrated to near dryness and chromatographed over silica gel using ethyl acetate and
hexane (1:1) to generate pure product 7 (0.23 g, 50%); m.p. 152-154 °C; IH NMR (300
MHz, CDCh): 83.09 (s, 3H), 5.23 (s, 2H), 7.15 (t, IH, J = 7.8 Hz), 7.33 (m, IH, J = 8.1
Hz), 7.53 (d, 2H, J = 8.1 Hz), 7.75 (d, 2H, J = 9.9 Hz), 7.95 (d, 2H, J = 8.1 Hz); 13C NMR
(CDCI 3): 844.0, 70.3, 94.2, 126.9, 127.5, 127.9, 128.2, 130.3, 135.4, 137.4, 138.1, 138.3,
141.9, 154.7, 171.8. Exact mass calculated for C17H13I04S mlz 439.9579; found m/z
439.9572.

4.2.5 Synthesis of 4-(4-Methanesulfonylphenyl)-3-[3-(4,4,S,s-tetramethyl-[1,3,2]
dioxaborolan-2-yl)phenyl]-5H-furan-2-one, 8.47
A 2-necked, 25 mL round-bottom flask was charged with 1,1-bis
(diphenylphosphino)ferrocene dichloropalladium [PdCh(dppf)] (23 mg, 0.03 mmol),
dppf(33 mg, 0.06 mmol), potassium acetate (0.30 g, 3.0 mmol), bis(pinacolato)diboron
(0.38g, 1.5 mmol) and flushed with nitrogen. A solution of 7 (0.44 g, 1.0 mmol) in 1,4
dioxane (5 mL) was added and the solution stirred for 24 h at 100°C. The mixture was
cooled to room temperature, 109 silica gel was added and the mixture was concentrated
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to dryness. The residue was subjected to column chromatography over silica gel using
ethyl acetate and hexane (6:4) to obtain pure product 8 (0.26 g, 57.2%), m.p. 181-183 °C;
IH NMR (300 MHz, CDCh): cS 1.32 (s, 12H), 3.05 (s, 3H), 5.20 (s, 2H), 7.41 (m,2H),
7.50 (d, 2H, J = 8.4 Hz), 7.84 (m, 2H), 7.90 (d, 2H, J = 8.4 Hz); 13C NMR (300 MHz,
CDCh): cS 24.8, 44.3, 70.3, 84.0, 128.0, 128.4, 128.5, 128.7, 129.3, 131.8, 135.3, 136.1,
138.3, 138.7, 141.9, 153.3, 172.3. Analytically calculated for C23H 2S B06S: C, 62.74; H,
5.72, S, 7.28. Found: 63.17,5.92, 7.03.

4.2.6 Syntbesis of Potassium 3-(3-trifluoroboro)-4-(4-metbanesulfonylpbenyl)
pbenyl-5H-furan-2-one, 9.47
Compound 8 (0.44 g, 1.0 mmol) was dissolved in MeOH (5 mL) and KHF2 (0.47
g, 6.0 mmol) dissolved in minimal water was added with stirring at room temperature.
After one hour, the mixture was concentrated to near dryness, dissolved in acetone, and
filtered. The filtrate was concentrated; and the product was recrystallized from CH3CN to
produce pure 9 (0.28 g, 65.3%); m.p. 281-283 °C; IH NMR (DMSO-~): cS 3.33 (s, 3H),
5.37 (s, 2H), 6.98 (bs, IH), 7.14 (bs, IH), 7.33 (bs, 2H), 7.61 (d, 2H, J = 6.6 Hz), 7.90 (d,
2H, J = 6.6 Hz); 13C NMR (DMSO-~): cS 43.1, 70.5, 125.8, 126.5, 127.2, 127.6, 128.5,
128.6, 131.9, 132.1, 133.1, 136.1, 141.7, 154.1, 173.0; 19F NMR (DMSO-~): cS -136.6.
Exact mass calculated for [C17HlSBF305Sr mlz 381.1; found mlz 381.2. Analytically
calculated for C17HI9BF3K07S: C, 43.05; H, 4.04; S, 6.76. Found C, 43.84; H, 3.18; S,
6.59.
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4.3

EXPERIMENTAL PROCEDURES FOR SYNTHESIS OF POTASSIUM 3

(4-TRIFLUOROBORO)-4-(4-METHANESULFONYLPHENYL)PHENYL-SH
FURAN-2-0NE, 12
4.3.1

Synthesis of 3-(4-Iodophenyl)-4-(methanesulfonylphenyl)-SH-furan-2-one,

10.
Ketone 6 (2.90 g, 10.5 mmol) and 4-iodophenyl acetic acid (2.20 g, 10.0 mmol)
were dissolved in acetonitrile (25 mL) in a clean, dry microwave tube. Triethylamine
(4.2 mL, 30.0 mmol) was slowly added with stirring. The tube was then placed in the
microwave and irradiated at 150 Watts for 20 minutes. The mixture was acidified with
aqueous INHCI (color changed from dark brown to light yellow). A mixture of ice and
water (200 mL) was added with stirring. The precipitate was filtered, rinsed with water,
dissolved in CH2Ch (20 mL) and then dried over anhydrous MgS04. The filtrate was
concentrated to near dryness and chromatographed over silica gel using ethyl acetate and
hexane (1:1) to generate pure 10 (2.28 g, 52%); m.p. 154-156 °C; IH NMR (250 MHz,
CDCh): 3.06 (s, 3H), 5.17 (s, 2H), 7.12 (d, 2H, J = 8.4 Hz), 7.50 (d, 2H, J = 8.4 Hz), 7.72
(d, 2H, J = 8.4 Hz), 7.92 (d, 2H, J = 8.4 Hz); 13C NMR (250 MHz, CDCI3): 044.2, 70.4,
95.8, 125.4, 126.2, 130.8, 135.9, 136.1, 138.4, 142.1, 154.1, 172.0. Exact mass
calculated for C17H13I04S mlz 439.9579; found mlz 439.9584.

4.3.2

Synthesis of 4-(4-Methanesulfonylphenyl)-3-[4-(4,4,S,S-tetramethyl-[1,3,2]

dioxaborolan-2yl)phenyl]-SH-furan-2-one, 11.47
A 2-necked, 25 mL round-bottomed flask was charged with 1,I-bis
(diphenylphosphino)ferrocene dichloropalladium [PdCh(dppf)] (23 mg, 0.03 mmol),
dppf(33 mg, 0.06 mmol), potassium acetate (0.30 g, 3.0 mmol), bis(pinacolato)diboron
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(0.38g, 1.5 mmol) and flushed with nitrogen. A solution of10 (0.44 g, 1.0 mmol) in 1,4
dioxane (5 mL) was added and the solution stirred for 16 h at 100°C. The mixture was
cooled to room temperature, 109 silica gel was added and the solvent removed under
reduced pressure to provide a powder. The powder was subjected to column
chromatography over silica gel using ethyl acetate and hexane (6:4) to obtain pure
product 11 (0.30 g, 66%), m.p. 182-184 °C; IH NMR (250 MHz, CDCh): 0 1.35(s, 12H),
3.07 (s, 3H), 5.20 (s, 2H), 7.38 (d, 2H, J = 7.6 Hz), 7.48 (d, 2H, J = 8.4 Hz), 7.63 (d,2H,
J = 8.0 Hz), 7.90 (d, 2H, J = 8.4 Hz); I3C NMR (250 MHz, CDCh): 024.8,44.2, 70.4,
84.0, 128.0, 128.3, 128.5, 128.6, 131.8, 135.1, 136.2, 138.1, 141.9, 154.0, 172.3. Exact
mass calculated for C23H2sB06S: m/z 440.1469; Found: m/z 440.1461.
4.3.3

Synthesis of Potassium 3-(4-trifluoroboro)-4-(4-methanesulfonylphenyl)

phenyl-5H-furan-2-one, 12.47
Compound 11 (0.44 g, 1.0 mmol) was dissolved in MeOH (5 mL) and KHF2
(0.47 g, 6.0 mmol) dissolved in minimal waterwas added with stirring at room
temperature. After one hour, the mixture was concentrated to near dryness, dissolved in
acetone, and filtered. The filtrate was concentrated and the product was recrystallized
from CH3CN to produce pure 12 (0.30 g, 70.0%); m.p. 283-285 °C; IH NMR (300 MHz,
DMSO-~):

0 3.23 (s, 3H), 5.36 (s, 2H), 7.06 (d, 2H, J = 7.8Hz), 7.33 (d, 2H, J

7.61 (d, 2H, J

= 7.5 Hz),

8.4 Hz), 7.91 (d, 2H, J = 8.1 Hz); 13C NMR (250 MHz, DMSO-~): 0

42.9, 70.4, 126.0, 126.8, 127.1, 127.7, 128.3, 131.4, 135.9, 141.5, 154.0, 172.7;

19p

NMR

(300 MHz, DMSO-~): 0 -139.0. Analytically calculated for C17HlsBF3KOSS: C,46.59;
H, 3.45; S, 7.32. Found C, 46.36; H, 3.39; S, 7.22.
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4.4

EXPERIMENTAL PROCEDURES FOR RADIOLABELING

4.4.1

Synthesis of 3-(3-[113I]Iodophenyl)-4-(methanesulfonylphenyl) -5H-furan-2

one, 1.47
Trifluoroborate 9 (100 ilL of5.2 x 10-2 solution in 50% aqueous tetrahydrofuran)
was placed in a 2 mL Wheaton vial containing no-camer-added Na I23I (37 MBq in 0.1 %
aqueous NaOH). To this was added peracetic acid (100 ilL, 0.3% solution in methanol).
The reaction vial was sealed, covered with aluminum foil, and the mixture stirred for 30
min at room temperature. A drop of 10% aqueous sodium thiosulfate was added to
decompose excess iodine and the radio iodinated product was isolated by passing it
through a silica gel Sep-Pak cartridge using petroleum ether: ethyl acetate (40:60) as
eluent. The radiochemical purity of 1 was determined by radio-TLC (aluminum backed
silica gel plate, petroleum ether:ethyl acetate = 40:60); Rr = 0.36. The TLC retention
time was identical to that of an authentic non radioiodinated sample. The radiochemical
purity was 92% and the decay corrected yield was 37%. HPLC separation of the
radiolabeled product was deemed unnecessary since TLC analysis of the eluent obtained
after Sep-pak separation showed no evidence of starting material or hydrolyzed by
products using ultraviolet light, phosphomolybdic acid. The total synthesis time was 40
min.

4.4.2

Synthesis of 3_(4_[1l3I] Iodophenyl)-4-(meth anesulfonylphenyl) -5H-furan-2

one, 2.47
Trifluoroborate 12 (100 ilL of5.2 x 10-2 solution in 50% aqueous tetrahydrofuran)
was placed in a 2 mL Wheaton vial containing no-camer-added Na123I (37 MBq in 0.1 %
aqueous NaOH). To this was added peracetic acid (100 ilL, 0.3% solution in methanol).
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The reaction vial was sealed, covered with aluminum foil, and the mixture stirred for 30
min at room temperature. A drop of 10% aqueous sodium thiosulfate was added to
decompose excess iodine and the radio iodinated product was isolated by passing it
through a silica gel Sep-Pak cartridge using petroleum ether: ethyl acetate (40:60) as
eluent. The radiochemical purity of 2 was determined by radio-TLC (aluminum backed
silica gel plate, petroleum ether:ethyl acetate = 40:60); Rf = 0.36. The TLC retention
time was identical to that of an authentic non radioiodinated sample. The radiochemical
purity was 98% and the radiochemical yield was 42%. HPLC separation of the
radiolabeled product was deemed unnecessary since TLC analysis of the eluent obtained
after Sep-pak separation showed no evidence of starting material or hydrolyzed by
products using ultraviolet light, phosphomolybdic acid, or iodine visualization the
radiochemical purity of the product exceeds 98% as revealed by radio TLC. The total
synthesis time was 40 min.
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Chapter 5

5.1

Conclusions and Future Work

CONCLUSIONS
In conclusion, two no-camer-added iodine-123 labeled rofecoxib analogues, 1

and 2, were synthesized as potential SPECT agents for imaging COX-2 receptor sites.
The syntheses involved an iododeboronation sequence. The high yield preparation has
the advantage that the reactive intermediates are hydrolytically and chemically stable
under normal laboratory conditions. Furthermore, because ofthe ionic nature of the
intermediates, they are readily separated from the lipophilic target molecules by simple
filtration using commercially available silica gel Sep-paks.

5.2

FUTURE WORK
Future work should focus on preparation ofthe ortho-derivative of the no-camer

added iodine-123 labeled rofecoxib analogue using the iododeboronation sequence. The
evaluation of both the prepared rofecoxib analogues 1 and 2 both in vitro and in vivo
should be investigated. Results from these studies could be correlated with their parent
structures and aid in the design of additional target molecules.
The syntheses of more complex rofecoxib analogues should also be explored, as
well as in vivo biodistribution studies of these target molecules.
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I H,

13C, and 19F NMR Spectra of Intermediate and Target Compounds
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